SHL Medical publishes its Molly® modular platform technology white paper
This white paper is a retrospective analysis on how the new generation of Molly autoinjectors have incorporated a greater level of flexibility in its design and development model.
SHL Medical, a world-leading solutions provider in the design, development, and manufacturing of self-injection devices, announced the publication of its white paper titled, “Molly® Autoinjector: A Systematic Review of Molly’s Integrated and Flexible Design and Development Model”.
With various platform autoinjector offerings emerging in the
market, SHL Medical sought to redefine the conventional platform model by
adding modularity to its Molly device technology. In 2010, SHL’s Molly was
originally designed to be a preconfigured offering leveraging communal
infrastructure to save costs and shorten timelines. The Molly technology has
since supported the commercial launch of 17 combination products covering at
least 25 clinical indications across various diseases areas. Ten years after,
the second generation of Molly was born – now a modularized technology that
goes beyond the confines of platform-based devices.
This white paper is a retrospective analysis on how the new
generation of Molly autoinjectors have incorporated a greater level of
flexibility in its design and development model. The work is a result of
research and discussions with various subject-matter experts from SHL’s
technical teams. It outlines SHL’s predictive response to market imperatives in
the medical device industry, resulting in a constantly expanding Molly
ecosystem that supports product customization and effective lifecycle
management.
Subdivided into three chapters, the white paper discusses and
analyzes:
- The Molly design and usability philosophy
- Modularized manufacturing infrastructure supporting the Molly autoinjector development and production
- Quality and regulatory systems that support Molly projects
“SHL’s Molly autoinjectors have been met with commercial successes spanning various disease areas and patient groups. This white paper provides evidence of SHL’s developmental work over the years to design a robust and adaptive autoinjector technology that addresses the requirements of pharma and their end users. Such a technology is exhibited in Molly’s flexibility as an autoinjector device offering seen in various layers of the whole device development stream. We are proud to share this work with our pharma partners for them to gain a comprehensive understanding of SHL’s customizable platform offering and how it can continuously support the ever-changing requirements of the medical industry, now and in the future,” SHL Medical Director of Marketing Magnus Fastmarken said.
SHL Medical’s Molly autoinjector white paper is now available for download.
More information about the modular autoinjector platform technology can be found on the dynamic Molly webpage.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance